TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 335 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q4 2019. The put-call ratio across all filers is 1.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $10,635 | -7.6% | 820 | 0.0% | 0.00% | – |
| Q2 2022 | $11,513 | -2.0% | 820 | 0.0% | 0.00% | – |
| Q1 2022 | $11,742 | +5.1% | 820 | 0.0% | 0.00% | – |
| Q4 2021 | $11,177 | -66.5% | 820 | -59.8% | 0.00% | -100.0% |
| Q3 2021 | $33,399 | -2.7% | 2,039 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $34,316 | -5.6% | 2,039 | +2.4% | 0.00% | -50.0% |
| Q1 2021 | $36,356 | +96.0% | 1,991 | +95.4% | 0.00% | +100.0% |
| Q4 2020 | $18,546 | -71.9% | 1,019 | -72.4% | 0.00% | -75.0% |
| Q3 2020 | $65,901 | +267.5% | 3,694 | +269.4% | 0.00% | +300.0% |
| Q2 2020 | $17,930 | +42.5% | 1,000 | +20.6% | 0.00% | 0.0% |
| Q1 2020 | $12,584 | -29.1% | 829 | -7.8% | 0.00% | 0.0% |
| Q4 2019 | $17,737 | +145.5% | 899 | +114.0% | 0.00% | 0.0% |
| Q3 2019 | $7,224 | +103.0% | 420 | +109.0% | 0.00% | – |
| Q2 2019 | $3,558 | +2.2% | 201 | +17.5% | 0.00% | – |
| Q1 2019 | $3,483 | – | 171 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Adelphi Capital LLP | 8,958,784 | $176,757,000 | 33.75% |
| Ovata Capital Management Ltd | 879,800 | $17,557,092,000 | 13.04% |
| Paulson & Co. | 13,244,711 | $261,318,000 | 5.64% |
| Glenview Capital Management | 30,582,721 | $603,397,000 | 5.28% |
| MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | 718,028 | $14,167,000 | 4.85% |
| Velanne Asset Management Ltd | 302,694 | $5,972,000 | 3.52% |
| Blackcrane Capital, LLC | 172,708 | $3,408,000 | 2.72% |
| Melqart Asset Management (UK) Ltd | 1,557,000 | $30,720,000 | 2.57% |
| GMT CAPITAL CORP | 3,345,976 | $66,016,000 | 2.55% |
| REDWOOD CAPITAL MANAGEMENT, LLC | 827,955 | $16,336,000 | 2.24% |